Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLUL | P15104 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GCLC | P48506 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980143 | 1.00 | GLUL (0.52) | GLULFOLH1PTGS1SLC7A11GCLC | |
| SCHEMBL8967238 | 1.00 | GLUL (0.52) | GLULFOLH1PTGS1SLC7A11GCLC | |
| SCHEMBL28229605 | 0.97 | GLUL (0.50) | GLULFOLH1PTGS1SLC7A11GCLC | |
| SCHEMBL23649439 | 0.97 | GLUL (0.50) | GLULFOLH1PTGS1SLC7A11GCLC | |
| Norvaline SCHEMBL6924739 | 0.85 | GCLC (0.53) | GLULGCLC | |
| SCHEMBL13892954 | 0.80 | PTGS1 (0.48) | GLULPTGS1SLC7A11GCLC | |
| SCHEMBL19697646 | 0.80 | PTGS1 (0.48) | GLULPTGS1SLC7A11GCLC | |
| SCHEMBL5054657 | 0.80 | PTGS1 (0.48) | GLULPTGS1SLC7A11GCLC | |
| SCHEMBL28341260 | 0.79 | GABBR2 (0.42) | GLULFOLH1 | |
| SCHEMBL13997104 | 0.77 | PTGS1 (0.44) | GLULPTGS1SLC7A11GCLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120324436-B | Medicine for treating T cell acute lymphoblastic leukemia and application thereof | People's Hospital Affiliated to Ningbo University (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| EP-3966344-B1 | KINASE SCREENING ASSAYS | UNIV NEWCASTLE (GB) | 2025-06-25 | — | — | EP | claimed |
| CN-115920039-B | Method for preparing ansamitocin P-3 loaded photo-responsive thermosensitive liposome by microfluidic technology and application | 常州大学 | 2025-05-06 | — | — | CN | claimed |
| WO-2025069991-A1 | ACTINIC-RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2025-04-03 | — | — | WO | claimed |
| CN-119677779-A | Combination therapy with anti-nucleolin 1 antibodies and antibody conjugates | 儿童医学中心公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119487077-A | Mutant and mislocalized cell surface nucleolin 1 as diagnostic and therapeutic targets for human diseases | 儿童医学中心公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2025026449-A1 | MODIFIED CELLS AND USES THEREOF | ST PHI THERAPEUTICS CO., LTD. (CN) | 2025-02-06 | — | — | WO | claimed |
| CN-118684620-A | Betel nut alkaloid and preparation method and application thereof | 暨南大学 | 2024-09-24 | — | — | CN | claimed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | claimed |
| US-20030202994-A1 | Excitatory amino acid inhibitors for treating sensitive skins | SOCIETE L'OREAL S.A. (FR) | 2003-10-30 | — | — | US | claimed |
| US-6506738-B1 | Treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection. | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-14 | — | — | US | claimed |
| EP-0795337-B1 | A method of preparing biological implantation material | SORIN BIOMEDICA CARDIO SPA (IT) | 2002-12-04 | — | — | EP | claimed |
| US-6001581-A | Cation-based bioassay using human metabotropic glutamate receptors | SIBIA NEUROSCIENCES, INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0904777-A1 | Use of an excitatory amino acids inhibitor in cosmetic or dermatological compositions for sensitive kin and composition obtained | L'OREAL (FR) | 1999-03-31 | — | — | EP | claimed |
| US-5873812-A | REDUCING PROSTHETIC ORGAN AND TISSUE REJECTION; BINDING EXCESS ALDEHYDE FIXATIVE BY TREATMENT WITH AN AMINOCARBOXYLIC ACID IN ACIDIC MEDIUM | SORIN BIOMEDICA CARDIO S.P.A. (IT) | 1999-02-23 | — | — | US | claimed |
| EP-0795337-A2 | A method of preparing biological implantation material | SORIN BIOMEDICA CARDIO S.p.A. (IT) | 1997-09-17 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| WO-1992019717-A1 | A HIGH-AFFINITY HUMAN GLUTAMATE/ASPARTATE UPTAKE SYSTEM | BAYLOR COLLEGE OF MEDICINE (US) | 1992-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GLUL 268/4885FOLH1 2718/4885PTGS1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.